• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Ask the Expert / Biologics – Injectables or IV – Patient Consensus?

Biologics – Injectables or IV – Patient Consensus?

April 5, 2007 By Arthritis Center

Question

I am sero negative RA (Still’s Disease). Because of initially diverse symptoms,diagnosis took a long time. When referred to a rheumatologist, she worked it up pretty quickly. Anyway, have been on methotrexate for several months and symptoms are actually worse. Prednisone taper worked for short time, but symptoms come back. Now on 7.5mg prednisone every AM in addition to the methotrexate. She would like to start me on the biologics and has given me information on the 3. In her experience, she has seen quicker response with Remicade (IV) than the injectables (Embrel and Humira). Possibly “related to the individual differences in tissue absorbtion of the injectables”. Other than that the way the 3 drugs work is pretty much the same and they have the same side effects. In addition to the usual questions that relate to insurance coverage, I am interested to know how your patients consider the convenience factors. That is, IV, 2 hours in the office every 4-8 weeks vs, weekly or bi-weekly injections. Also, have you seen much difference in the 3 drugs and from a cost basis, how does 6 doses of Remicade go up against 26-52 of the injectables.

Answer

I do not think the convenience factor is a big issue. Most patients receive Remicade very 2 months and thus the 2 hour infusion is not much of a big deal. Most use the time to nap or catch up on reading. However in the workalcoholic world, many of the younger working patients prefer the self injectionables. The cost of the agents is relatively similar, but Remicade is more expensive if the dose is increased. Humira can also be more expensive if increased to weekly dosing, but most patients are on every other week dosing.

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Primary Sidebar

Ask The Expert Topics

  • Alternative Therapies
  • Ankylosing Spondylitis
  • Associated With Other Illnesses
  • Bursitis and Tendinitis
  • Corticosteroids
  • Diet and Exercise
  • Disease Modifying Antirheumatic Drugs (DMARDs)
  • Enteropathic Arthritis
  • Fibromyalgia
  • General Arthritis
  • Gout, Pseudogout, Other
  • Infectious Arthritis
  • Myositis
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Osteoarthritis
  • Osteonecrosis
  • Osteoporosis
  • Polymyalgia Rheumatica
  • Psoriatic Arthritis
  • Reactive Arthritis
  • Regional Pain: Back and Neck
  • Rehabilitation
  • Rheumatoid Arthritis
  • Surgical Therapy
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis
  • Vasculitis
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy